Related Experiment Videos
Paraneoplastic pemphigus treated with dexamethasone/ cyclophosphamide pulse therapy
L R Becker1, B C Bastian, U Wesselmann
1Department of Dermatology, University of Würzburg, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany. becker-lr@mail.uni-wuerzberg.de
European Journal of Dermatology : EJD
|January 16, 1999
Summary
Paraneoplastic pemphigus (PNP), an autoimmune blistering disease, showed significant improvement with dexamethasone and cyclophosphamide pulse therapy. This treatment also effectively reduced Waldenström's macroglobulinemia markers.
Area of Science:
- Autoimmune diseases
- Dermatology
- Oncology
Background:
- Paraneoplastic pemphigus (PNP) is a rare, severe autoimmune blistering disease often linked to hematological malignancies.
- Waldenström's macroglobulinemia is a lymphoproliferative disorder characterized by IgM monoclonal gammopathy.
Observation:
- A patient with Waldenström's macroglobulinemia presented with clinical, histological, and immunopathological features consistent with PNP.
- The patient experienced significant improvement in cutaneous and mucosal lesions within two weeks of initiating i.v. dexamethasone and cyclophosphamide pulse therapy.
Findings:
- Dexamethasone/cyclophosphamide pulse therapy led to a marked reduction in IgM lambda serum levels, indicating a positive effect on the underlying macroglobulinemia.
- Despite initial success, severe stomatitis recurred three months after the second pulse, leading to therapy cessation by the patient.
Implications:
- Dexamethasone/cyclophosphamide pulse therapy presents a potentially effective treatment option for the challenging mucocutaneous manifestations of PNP.
- This therapeutic approach may offer benefits for both the autoimmune blistering disease and the associated hematological malignancy.